Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03449108
Title Iovance Alliance: LN-145 Across Multiple Tumor Types
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

sarcoma

ovarian cancer

osteosarcoma

Therapies

Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.